Abzena
The Science and Scale Behind Next-Generation Conjugates
Geoffrey Glass, Chairman and CEO
ADC and AOC CDMO Solutions
ADC and AOC CDMO solutions help biopharmaceutical companies develop and manufacture complex conjugate therapies through specialized outsourcing support. With a focus on process development, linker chemistry, quality control and regulatory readiness, they support safer production and more reliable therapeutic advancement.
Solutions
When it comes to developing next-generation modalities like antibody-oligonucleotide conjugates (AOCs), the partners who are best positioned to advance these programs don’t fit the conventional CDMO model. Building an effective and manufacturable AOC demands specialized expertise, the kind that only comes from decades spent mastering the junction of bioconjugation and antibody design and development. While AOCs build on ADC bioconjugation, oligo payloads introduce a distinct set of challenges that reshape how chemistry, linker selection and analytical characterization must be approached. That's why selecting the right development partner at the start of a program is critical to an AOC’s success.
State of Industry
Advancing Targeted Therapies with Next Generation ADC and AOC CDMO Solutions
The field of targeted therapy development is evolving rapidly as pharmaceutical and biotechnology companies pursue more precise treatments for complex diseases. Antibody drug conjugates and antibody oligonucleotide conjugates are reshaping the therapeutic landscape by combining selective targeting with advanced payload delivery. This shift has increased the importance of specialized contract development and manufacturing organizations that can support the intricate processes involved in ADC and AOC production.
Deep Dive
Choosing an ADC and AOC CDMO Partner for Complex Bioconjugates
Few development decisions carry greater downstream consequences than selecting a CDMO for antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs). Scientific promise alone rarely determines whether a program reaches the clinic on schedule. Process transfer delays, fragmented development ownership and manufacturing approaches that fail to scale often become the larger sources of cost and timeline risk. For emerging biotechnology companies working against limited funding windows, every additional handoff introduces another opportunity for delay.
Leadership Perspective
Biomerics
Quality In The World Of Medical Device Contract Manufacturing
Stacey Lyons, Director of Quality
Having an effective quality management system (QMS) is required for any medical device company. Having a focus on the safety, function, and efficacy of the product you manufacture is how you are successful within your QMS. The regulations of the Food and Drug Administration (FDA) and International Standards Organization (ISO) will require your compliance to be able to manufacture medical devices. FDA and ISO standards are written clearly but with little detail as to the ‘How-To’s’ of applying the standard. There are many guidance documents and white paper guidelines that can help with the application of the standards. The most important guideline to creating an effective QMS is assembling the proper quality group for ideal support of the QMS. Creating your QMS and quality group to fit your organization and device is pivotal. In my experience, your QMS systems are primarily based around branches, with your systems spread across the branches. If you can assign branches and systems within your company properly, it allows you to organize what is needed to follow the regulations. The branches and systems of the QMS can be defined no matter the size of the organization or the class of device. When it comes to branches, bucketing your group into quality systems, quality engineering, and quality control can allow you to isolate your systems and become more effective.
ADC and AOC CDMO Solutions Info
Q1
What Do Top ADC & AOC CDMO Solutions Providers Do?
Top ADC & AOC CDMO Solutions providers support the development and manufacturing of antibody-drug conjugates and antibody-oligonucleotide conjugates for pharmaceutical and biotechnology organizations. Their role may span process development, analytical work, conjugation, manufacturing, clinical supply and commercial-scale production. Because these therapies combine multiple complex components, CDMOs must coordinate scientific, technical and manufacturing activities to maintain product quality and consistency as programs advance.
Q2
What Services Are Typically Included in ADC and AOC CDMO Programs?
ADC and AOC CDMO services can include process and analytical development, antibody production, linker and payload handling, conjugation, purification, characterization and GMP manufacturing. Depending on the provider, support may also extend to technology transfer, scale-up, clinical supply and commercial manufacturing. Top ADC & AOC CDMO Solutions are valuable when organizations need specialized capabilities that can support multiple stages of development while reducing fragmented handoffs between technical teams.
Q3
Why Is Demand Growing for ADC and AOC CDMO Expertise?
Demand is increasing as drug developers pursue more targeted and complex therapeutic modalities that require specialized development and manufacturing capabilities. ADC and AOC programs create technical challenges involving molecular design, conjugation, analytical characterization, process control and scale-up. Top ADC & AOC CDMO Solutions help address these needs by providing expertise and infrastructure that many drug developers may not maintain internally, especially when programs must progress efficiently through preclinical and clinical stages.
Q4
How Are Top ADC & AOC CDMO Solutions Evaluated?
Organizations evaluating Top ADC & AOC CDMO Solutions often look at scientific expertise, experience with complex conjugates, development capabilities, manufacturing capacity, analytical capabilities and quality systems. They may also consider whether a provider can support a program from early development through larger-scale production. Decision-makers may assess how well it manages technical risks, keeps processes consistent, meets project timelines and adjusts its capabilities as a therapy moves into later clinical stages or commercial production.
Q5
How Do ADC and AOC CDMOs Create Value for Drug Developers?
The value of Top ADC & AOC CDMO Solutions lies in helping drug developers manage complexity without building every specialized capability internally. Effective outsourcing can reduce technical gaps between development and manufacturing, support more reliable scale-up and improve readiness for regulatory and clinical milestones. For emerging biotech organizations, access to experienced teams and established infrastructure can also help preserve capital and internal resources while keeping development programs focused on scientific and business priorities.
Q6
What Role Do Innovation and Technology Play in This Category?
Innovation is central to Top ADC & AOC CDMO Solutions because these modalities depend on precise control of complex biological and chemical processes. Advances in conjugation methods, analytical technologies, process development and manufacturing systems can improve product understanding and support greater consistency. Scientific expertise remains equally important, as technology alone cannot address every development challenge. Strong CDMO capabilities combine specialized platforms with practical knowledge of scale-up, quality requirements and the evolving needs of complex therapeutic programs.
